Clinical Trials Logo
  1. Home
  2. CRC
  3. NCT05233332

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) — mCRC  

CRC Clinical Trial

Official title:
A Phase Ⅱ, Multicenter Open-label Study to Investigate the Efficacy and Safety of HL-085 Combined With Vemurafenib in Patients With Metastatic Colorectal Cancer (mCRC)

Clinical Trial Summary

The study consists of the two parts, phase IIa and phase IIb.

Clinical Trial Description

The study consists of the two parts, phase IIa and phase IIb. Phase IIa study is to assess the safety and the antitumor activity in patients with mCRC and to recommend reasonable dosage regimen of HL-085 for phase IIb study. Phase IIb is a pivotal study to evaluate HL-085 plus Vemurafenib in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05233332
Study type Interventional
Source Shanghai Kechow Pharma, Inc.
Contact Zhimei Zhu, Master
Phone 86 215201345822
Email zhuzm@kechowpharma.com
Status Recruiting
Phase Phase 2
Start date February 24, 2022
Completion date July 20, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Active, not recruiting NCT01308086 - Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer Phase 3
Active, not recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Completed NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03336658 - Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
Recruiting NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Phase 1/Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT05382377 - NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors Early Phase 1
Active, not recruiting NCT05314309 - Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening
Recruiting NCT06259552 - A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors Phase 1
Completed NCT05976282 - Addressing Colorectal Cancer in South Florida Firefighters N/A
Recruiting NCT01593098 - A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
Recruiting NCT03597581 - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer Phase 1
Terminated NCT05368688 - Microbiome in Colorectal Cancer Onset and Progression
Completed NCT03965845 - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06455254 - Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM Phase 2
Not yet recruiting NCT03601598 - A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC Phase 1/Phase 2
Completed NCT02161549 - Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy N/A